Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pain 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × Baclofen × Clear all
NCT00493428 2014-05-16

Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study

University of Manitoba

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡